Skip to content
Preprint · CC-BY via OpenAlex

Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis

Zhen Yu, Shuai Tong, Can Zhang, Yue Yu Bai, Zhijing An, Chang Xu, Fang Wang, Yi Hu, Qinghui Zhuang, Xiaosong Zhong

Research Square · 2022 · ▲ 3 citations

Abstract

Abstract Chimeric antigen receptor (CAR)-modified T cells targeting antigens expressed on tumor cells have exhibited significant antitumor effects on several types of hematological malignancies, including acute myeloid leukemia, lymphoma, B cell maturation antigen, and CD19-positive acute lymphoblastic leukemia. However, several drawbacks, particularly the poor persistence, limit the use of CAR-T cell-based therapy. Nicotinamide mononucleotide (NMN), the precursor of nicotinamide adenine dinucleotide (NAD+), has been shown to reverse age-related complications and slow the aging rate by enhancing NAD+ levels in the body. However, whether NMN treatment could enhance the longevity and persistence of CAR-T cells and improve their antitumor efficacy is still unclear. In this study, we observed that NMN treatment limited differentiation and significantly increased stem cell–like memory (Tscm) and stem cell–like memory (Tcm) in CD19 CAR-T cells. In addition, both telomerase length and proliferation ability were increased, whereas apoptosis was reduced after NMN treatment of CD19 CAR-T cells. High-throughput sequencing data indicated that NMN treatment upregulated Sirt1 expression in CD19 CAR-T cells and downregulated genes downstream of Sirt1, such as NF-κB, TP53, and Bax. Animal experiments showed that NMN treated CAR-T cells exerted great antitumor efficacy in human xenografted mouse models. In conclusion, NMN enhances the efficacy and longevity of CD19 CAR-T cells via the NAD+–Sirt1 axis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.21203/rs.3.rs-1483519/v1
Canonical
link ↗
Fetched
2026-10-09 MST

Cite this

APA
Yu, Z., Tong, S., Zhang, C., Bai, Y.Y., An, Z., Xu, C., Wang, F., Hu, Y., Zhuang, Q., &amp; Zhong, X. (2022). Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-1483519/v1
Vancouver
Yu Z, Tong S, Zhang C, Bai YY, An Z, Xu C, et al. Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis. Research Square. 2022. doi:10.21203/rs.3.rs-1483519/v1.
BibTeX
@unpublished{zhen2022Nicoti, title = {Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis}, author = {Zhen Yu and Shuai Tong and Can Zhang and Yue Yu Bai and Zhijing An and Chang Xu and Fang Wang and Yi Hu and Qinghui Zhuang and Xiaosong Zhong}, journal = {Research Square}, year = {2022}, doi = {10.21203/rs.3.rs-1483519/v1}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings